Linda MasatVice President of Business Development at Trianni, Inc.
Dr. Masat has over 20 years of experience in discovering therapeutic antibodies and in accelerating development of transformational medicine through scientific innovation, strategic alliances and business transactions. She joined Trianni Inc. as VP of Business Development in 2018, where she successfully licensed the Trianni Mouse platform to multiple biotech and pharma organizations. Prior to joining Trianni, Linda was Director, Strategic Academic Alliances at Takeda Pharmaceutical, where she established and led collaborations with multiple academic and early-stage company innovators. Prior to this role, Dr. Masat led multidisciplinary teams at Takeda, XOMA and Abgenix (now Amgen) in the discovery and preclinical development of therapeutic antibodies to over 100 targets. She is the inventor of XOMA’s gevokizumab, licensed to Novartis in 2017. Dr. Masat received her Ph.D. in Biochemistry from the University of Urbino, Italy and did her postdoctoral training at the University of California, San Francisco.